Fluidx Completes Enrollment in Trial for GPX Embolic Device

September 1, 2022—Fluidx Medical announced the completion of enrollment in a trial for its GPX embolic device. In the multicenter trial, GPX was used to treat a variety of primary and metastatic tumors, renal adenoma tumors, and a range of other arterial and venous applications. The GPX embolic device is under development and does not have marketing clearance or approval in any market, advised the company.

According to Fluidx, GPX has shown promising results for tumor embolization and other uses where there is a desire for distal vessel bed penetration. The company noted that interim results of the GPX study have been presented at recent annual congresses including Global Embolization Symposium & Technologies, Society of Interventional Radiology, and Leipzig Interventional Course.

The trial’s principal investigator is Andrew Holden, MBChB, who is Director of Interventional Radiology at Auckland City Hospital in Auckland, New Zealand.

“We are pleased to announce the enrollment of the final patient in the trial and look forward to participating in future trials using this promising technology,” commented Dr. Holden in the company’s press release. “In the trial, GPX showed significant potential to advance liquid embolics, penetrating very distally, providing profound embolization, and demonstrating excellent radiopacity, which helped to avoid nontarget embolization and preserve healthy adjacent tissue.

“We've only touched on some of the applications. Further trials will provide opportunities to look at broader applications of this product. We believe it will be an exciting addition to the embolic portfolio for interventionalists.”

The GPX technology is a low viscosity, aqueous-based solution in a syringe that solidifies into a durable embolus upon delivery without polymerization or dimethyl-sulfoxide precipitation. It is designed for simple preparation and controllable material delivery, stated Fluidx.